Jazz Pharmaceuticals (NASDAQ:JAZZ) Releases FY 2025 Earnings Guidance

Jazz Pharmaceuticals (NASDAQ:JAZZ) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 22.500-24.000 for the period, compared to the consensus estimate of 24.000. The company issued revenue guidance of $4.2 billion-$4.4 billion, compared to the consensus revenue estimate of $4.3 billion. Jazz Pharmaceuticals also updated its FY 2025 guidance to 22.500-24.000 EPS.

Jazz Pharmaceuticals Trading Up 2.2 %

Jazz Pharmaceuticals stock traded up $2.98 during mid-day trading on Tuesday, hitting $139.67. 1,228,161 shares of the stock were exchanged, compared to its average volume of 634,225. The firm’s fifty day simple moving average is $125.08 and its two-hundred day simple moving average is $118.24. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals has a 12 month low of $99.06 and a 12 month high of $140.52. The stock has a market capitalization of $8.44 billion, a price-to-earnings ratio of 19.67, a PEG ratio of 1.04 and a beta of 0.56.

Analyst Ratings Changes

Several research firms have recently weighed in on JAZZ. HC Wainwright reissued a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $130.00 to $170.00 in a research report on Thursday, February 13th. Robert W. Baird boosted their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research report on Monday, November 18th. Royal Bank of Canada reissued an “outperform” rating and set a $179.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 10th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $163.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. One investment analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Buy” and an average target price of $180.33.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 2,000 shares of Jazz Pharmaceuticals stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $121.17, for a total transaction of $242,340.00. Following the transaction, the chief executive officer now directly owns 427,025 shares of the company’s stock, valued at $51,742,619.25. The trade was a 0.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 5,053 shares of company stock valued at $617,442 over the last 90 days. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.